Aid in the prevention of disease and mortality caused by 4 virulent Leptospira serovars21
Protects against liver dysfunction and thrombocytopenia1
The only vaccine indicated to protect against mortality and leptospiruria
Prevents leptospiremia22
Proven safe and well tolerated in multiple studies1
Available in both a stand-alone and combination formulation (DAPPv)
INDICATIONS:
Shown to be effective against disease and mortality caused by L. canicola, L. icterohaemorrhagiae, L. pomona, or L. grippotyphosa.
Prevents leptospiruria associated with L. grippotyphosa, L. canicola, or L. icterohaemorrhagiae.
Aids in the prevention of leptospiruria associated with L. pomona.
Recommended for use in healthy dogs 8 weeks of age or older.
Unmatched Protection of Nobivac® Lepto4:Two Critical Indications
1. SHEDDING: DEFENSE AGAINST URINARY SHEDDING CAUSED BY 4 KEY LEPTOSPIRA SEROVARS
PREVENT URINARY SHEDDING OF LEPTOSPIRES22
A key objective of vaccination is to prevent urinary shedding of leptospires, which has potential zoonotic risk:22,23
0% of dogs vaccinated with Nobivac® Canine 1-DAPPv+L4 developed leptospiruria
All of the control dogs challenged with L. canicola and L. grippotyphosa, 80% of control dogs challenged with L. icterohaemorrhagiae, and 50% of control dogs challenged with L. pomona developed leptospiruria
Nobivac® Lepto4 is shown to be effective against leptospiruria associated with
L. grippotyphosa
L. canicola
L. icterohaemorrhagiae
L. pomona
UNMATCHED PROTECTION
NOBIVAC LEPTO4 IS THE CLEAR CHOICE WHEN COMPARED WITH OTHER 4-WAY LEPTOSPIROSIS VACCINES24-27
To promote an even higher level of vaccine quality, Merck Animal Health introduced the unique VacciPure filtration process for manufacturing Nobivac® Lepto4 and Nobivac® Canine 1-DAPPV+L4.
A porous filtration membrane selectively removes extraneous proteins, salts, and solvents
The outcome – fewer total proteins and a more purified final product
